Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

Fineline Cube Sep 12, 2025

Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...

Company Policy / Regulatory

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

Fineline Cube Sep 12, 2025

The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...

Company

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US

Fineline Cube Sep 12, 2025

US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...

Company Drug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration

Fineline Cube Sep 12, 2025

Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...

Drug Policy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Fineline Cube Sep 12, 2025

The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...

Company Drug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

Fineline Cube Sep 11, 2025

China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Deals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Fineline Cube Sep 11, 2025

China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...

Company Deals Drug

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

Fineline Cube Sep 11, 2025

Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...

Company Deals

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront

Fineline Cube Sep 11, 2025

The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...

Company Drug

Novartis Secures Tabrecta Approval in China for METex14 NSCLC

Fineline Cube Sep 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...

Company Drug Policy / Regulatory

China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls

Fineline Cube Sep 11, 2025

At a State Council Information Office press conference, Deputy Director of the National Health Commission...

Policy / Regulatory

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings

Fineline Cube Sep 11, 2025

The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...

Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

Fineline Cube Sep 11, 2025

The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...

Company Drug

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination

Fineline Cube Sep 11, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...

Company Deals

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access

Fineline Cube Sep 11, 2025

Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...

Company Drug

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar

Fineline Cube Sep 11, 2025

China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors

Fineline Cube Sep 11, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...

Company Deals

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development

Fineline Cube Sep 10, 2025

China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...

Company Deals Medical Device

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis

Fineline Cube Sep 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...

Posts pagination

1 … 99 100 101 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.